In an ongoing patent dispute with Masimo, redesigned models of Apple Watch, notably lacking a blood oxygen monitor, are not slated to face an import ban as confirmed by the U.S. Customs and Border Protection. This verdict appeared in a court filing put forth by Masimo on a recent Monday.
This dispute follows reports where Masimo alleged that Apple infringed on its patent rights particularly for the non-invasive measurement of various physiological parameters – a feature inherent to earlier Apple Watch models equipped with a blood oxygen monitoring device
The strategy of redesigning key devices presents an effective loophole, shielding major corporations from legal sanctions in ongoing patent warfare. In this case, Apple’s clever move has ensured the uninterrupted import of their smartwatches sans the disputed technology.
This skirmish underlines the importance of intellectual property rights protection for novel technologies in a competitive environment – a considerable concern for not only the giants like Apple but also smaller innovators like Masimo.